Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leht 1 alates 40 tulemused
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and that such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or have
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or have
Use of isatin derivatives as ion channel activating agents
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
The present invention relates to ion channel activating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as openers of SK.sub.Ca and IK.sub.Ca channels. In further aspects, the present invention relates to the
Compositions and methods for the treatment of severe pain
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1838/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050917 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this
Non-natural galanin receptor ligands
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to non-natural galanin receptor ligands which can function as agonists and antagonists of galanin and can be used to treat diseases or conditions in which galanin plays a role.
BACKGROUND OF THE INVENTION
Galanin.sup.1 is a 29/30 amino acid long neuroendocrine peptide
Therapeutic use of compounds
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This invention relates to uses of compounds. In particular, it relates to the use of compounds in the treatment or prevention of diseases and biomedical conditions such as, seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent
Adenosine receptor agonists, partial agonists, and antagonists
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
There are four subtypes of receptors for adenosine, designated A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3. The A.sub.3 adenosine receptor is found primarily in the central nervous system, brain, testes, and the immune system, where it appears to be involved in the
Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention The present invention relates to novel tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidine compounds that are antagonists of alpha V (.alpha.v) integrins, for example .alpha..sub.v.beta..sub.3 and .alpha..sub.v.beta..sub.5 integrins, their
Bumetanide analogs, compositions and methods of use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, including derivatives, positional isomers, and prodrugs thereof, compositions comprising the same and methods of making and using the same. The present invention also relates
Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This application is the United States national stage of International Application No. PCT/EP01/15289, filed Dec. 21, 2001, which was published under PCT Article 21(2) in English as International Publication No. WO 02/051438, and which claims benefit of European Patent Application No. 00128356.3
Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND TO THE INVENTION
The present invention is generally in the field of therapeutic formulations for delivering gamma-hydroxybutyrate.
Gamma-hydroxybutyrate ("GHB") is a naturally occurring substance that is widely distributed in the mammalian body, being present, for example, in the brain,
Bisarylamines as potassium channel openers
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention relates to the use of certain bisarylamines as potassium channel openers and to the treatment of diseases modulated by potassium channel opening. Additionally, this invention relates to novel compounds that are useful as potassium channel openers.
BACKGROUND OF
Heterocycles as potassium channel modulators
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Ion channels are cellular proteins that regulate the flow of ions, including calcium, potassium, sodium and chloride, into and out of cells. These channels are present in all human cells and affect such processes as nerve transmission, muscle contraction and cellular
Heterocycles as potassium channel modulators
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Ion channels are cellular proteins that regulate the flow of ions, including calcium, potassium, sodium and chloride, into and out of cells. These channels are present in all human cells and affect such processes as nerve transmission, muscle contraction and cellular
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
